key: cord-0999625-x3jxkxyt
authors: Joshua Adedeji, Bolarin; Mercy Adaramodu, Oluwatoyosi; Iseoluwa Orege, Joshua; Emmanuel Ayodeji, Ayeni; Yusuf Ajibola, Ibrahim; Sherif Babatunde, Adeyemi; Bolaji Tiamiyu, Bashir; Lanre Anthony, Gbadegesin; Oluwadara Akinyemi, Toluwanimi; Kenneth Odoh, Chuks; Ijeoma Umeobi, Happiness; Adenike Bernice-Eloise, Adeoye
title: Therapeutic Drugs for SARS-CoV-2 Treatment: Current State and Perspective
date: 2020-11-27
journal: Int Immunopharmacol
DOI: 10.1016/j.intimp.2020.107228
sha: 06c257208ff60f1c5f6e10862de22b9fb42f4375
doc_id: 999625
cord_uid: x3jxkxyt

The disease caused by viral pneumonia called severe acute respiratory syndrome coronavirus type-2 (SARS-CoV-2) declared by the World Health Organization is a global pandemic that the world has witnessed since the last epidemic of Ebola, SARS and MERS viruses. Many chemical compounds with antiviral activity are currently undergoing clinical investigation in a bid to finding a potent therapy for treating infected patients. On-going drug-drug interaction examinations on new, existing, and repurposed antiviral drugs are yet to provide adequate safety, toxicological, and effective monitoring protocols. This review, therefore, presents an overview of direct and indirect antiviral drugs, antibiotics, and immune-stimulant drugs used in the management of SARS-CoV-2. It also seeks to outline the recent development of drugs with anti-coronavirus effects; their mono and combination therapy in managing the disease vis-à-vis their biological sources and chemistry. Co-administration of these drugs and their interactions were discussed to provide significant insight into how adequate monitoring of patients towards effective health management could be achieved.

Since time immemorial, there has been a periodic recurrence of viral outbreaks at both epidemic and pandemic levels. In the recent past were severe acute respiratory syndrome coronavirus (SARS-CoV), These compounds include Ribavirin, Lopinavir-ritonavir, Chloroquine, Favipiravir, and Arbidol 10 .

Other drugs that are still undergoing clinical trials with promising activity include Remdesivir, Atazanavir, Presatovir, Carmofur, Emetine dihydrochloride, and Omacetaxince (Homoharringtonine), Azithromycin Ivermectin, Colchicine, TMPRSS2 and Interferon α, were also discussed. The clinical features of these drugs and their mechanisms of action/target, EC 50 , and CC 50 were reviewed and summarized in Table 1 .

This is an FDA approved compound usually referred to as synthetic guanosine analogue with antiviral potential (Fig 1a) . It is used as a blend with other antiviral drugs and in most cases with interferon-alpha (IFN-a) for the treatment of several viral infections such as chronic hepatitis C virus, viral hemorrhagic fever, and respiratory syncytial virus 11 . Ribavirin was first commercialized in the early 1980s for the treatment of respiratory syncytial virus in children which makes it a premier and standard antiviral agent over the newly developed drugs. Aside from being regarded as a broad-spectrum antiviral agent against DNA and RNA which can obscure the production of viral messenger RNA binding RNA-dependent RNA polymerase (RpRd), it is also a prodrug that metabolizes into nucleoside analogues blocking viral RNA and viral mRNA capping 12 . Ribavirin was found to be effective against Crimean-Congo hemorrhagic fever, Hantavirus infection, Lassa fever, and Venezuelan hemorrhagic fever. Meanwhile, promising results had emanated previously about the blend of ribavirin with Interferon-alpha for the treatment of MERS-CoV 13 . Conflicting data have equally been reported for patients with MERS-CoV infection that were treated with a blend of ribavirin and two forms of interferon-a; IFN-a 2b and IFN-b1 14 . It can affect haemoglobin (Hb) counts of the red blood cells which is an undesirable side effect in patients with respiratory disorders; a feature that reduces its potential as a potent antiviral agent against coronavirus infection. However, during the SARS-CoV outbreak in 2003, few countries including China and Canada successfully administered high doses of a blend of ribavirin with antibiotics and hormone against the virus 15 . A possible combination of ribavirin with lopinavir-ritonavir has proven to be potent against SARS COV-2 16 .

This is a newly discovered RNA-dependent RNA polymerase (RdRp) inhibitor similar to ribavirin earlier discussed (Fig 1b) . Apart from its anti-influenza viral activity, clinical experiments have revealed that it is capable of blocking the replication of flavi-, alpha-, filo-, bunya-, arena-, noro-, and other RNA viruses 17 . Favipiravir when in cells is transformed into an active phospho-ribosylated (F-RTP), a form that is recognized by viral RNA polymerase as a substrate thus inhibiting its activity in patients 18 People's Hospital of Shenzhen conducted a clinical trial on 14 th February 2020 and obtained promising results. The preliminary results showed that the antiviral efficiency of Favipiravir is more than that of Lopinavir-ritonavir blend 19 .

Arbidol is known as "Umifenovir" (Fig 1c) is an active antiviral agent that has greatly been used for the treatment of the influenza virus. For decades, it has been an effective agent, with no reported side effect, commonly administered in China and Russia to prevent severe pneumonia and cytokine dysregulation associated with viral infections 20 . It is a broad-spectrum antiviral agent with both in vitro and in vivo inhibitory potentials against various infectious diseases such as influenza, hepatitis B virus (HBV), hepatitis C virus (HCV), Hantaan virus, and other pathogenic human respiratory viruses. Aside from enhancing the immune response of host cells, Arbidol actively inhibits the binding of viral cell walls with the membrane of target cells, thus preventing its entry 21 . Arbidol has now been nominated as a first-aid therapy against novel coronavirus and studies are ongoing towards further optimization [22] [23] [24] 

This is a medication usually administered in combination with other antiviral drugs such as ribavirin (earlier described) for treating Human Immunodeficiency Virus HIV 25 . It (Fig 1d) belongs to a class of protease inhibitors capable of targeting SARS-CoV non-structural protein 3Clpro 16 Nevertheless, it has been recommended as an effective anti-SARS-CoV-2 agent in China 16 . Further investigations are ongoing by some Chinese researchers/clinicians into the therapeutic efficiency of Lopinavir-ritonavir.

Remdesivir is one of the most promising antiviral drugs tested for the treatment of coronavirus infection.

It is a phosphoramidite prodrug of adenosine nucleotide 28 with a broad-spectrum in-vitro antiviral activity against a wide range of RNA viruses like Ebola virus, respiratory syncytial virus, Nipah virus, Hendra virus, Marburg virus, pathogenic viruses such as MERS-CoV and SARS-CoV and bat CoV strains 29, 30 . Although it is a nucleotide analogue, Remdesivir has shown to inhibit viral RNA replication, prematurely terminate viral RNA transcription by targeting viral RNA-dependent RNA polymerase, and evade viral exoribonuclease proofreading 31 . To date, pharmacokinetic and clinical detail on Remdesivir is still obscure. However, critical investigations are ongoing. Markedly, concerns of antiviral resistance against its usage have been studied 31 . Very recently, the antiviral activity of Remdesivir was examined at an early stage after virus entry into Vero E6 cells detailing its mechanism of action as a nucleotide 32 . The EC 90 results were observed to be 1.76 μM, suggesting its potency against the virus. In a mouse model study on SARS-CoV-2 pathogenesis, prophylactic and therapeutic activity 32 observed that early administration of the drug reduced lung viral load by an order of magnitude greater than 2 on day 4 or 5 post-infection, restrained the disease and improved respiratory function.

More so, in a tissue culture model, a biologically important in vitro model of pulmonary infection, Remdesivir displayed low half-maximal effective concentrations (EC 50 s) of 0.069 and 0.074 μM for SARS-CoV and MERS-COV respectively which revealed its effectiveness against a wide range of highly divergent coronaviruses like the endemic CoVs hCoV-OC43 and hCoV-229E within the submicromolar EC 50 29,33 . In another animal model examination, a rhesus monkey model on the Ebola virus, 10 mg/kg dose administered daily for consecutive 12 days inhibits the Ebola virus replication and protects all infected animals against infection 34 . Based on the successful clinical experience of Remdesivir therapy on Ebola virus patient 35 as well as on the first SARS COV-2 confirmed case in Washington, United States of America (with a negative swab at day 1 after treatment) has suggested that Remdesivir is a promising antiviral therapy for COVID-19 treatment. The molecular mass of Remdesivir is 602.6 g/mol with a chemical formula of C 27 H 35 O 8 P (Fig 1e) .

This is another anti-retroviral FDA approved medication commonly used for HIV treatment and prevention. Atazanavir is distinguished from other protease inhibitors in that it can only be administered one daily rather than requiring multiple doses per day and has lesser effects on the patient's lipid profile 36, 37 . As an azapeptide HIV-1 protease inhibitor, atazanavir binds to the protease active site and inhibits the enzyme activity. Owing to its antiviral activity 38 against SARS-CoV-2 3C-like protease. This protease enzyme is also found in coronaviruses due to its cleavage potentials to the coronavirus polyprotein at different conserved sites. Atazanavir (Fig 1f) has a molecular weight of 704g/mol.

Carmofur is another promising candidate drug that has shown to inhibit SARS-CoV-2 main protease (Mpro) enzymes responsible for many coronaviruses with a half-maximal effective concentration (EC 50 ) of 24.30 μM and a half-maximal inhibitory concentration (IC 50 ) of 1.82 μM, showing its ability to inhibit viral replication in cells 39 . It is a derivative of fluorouracil, an antineoplastic agent that has demonstrated clinical benefit as a cancer therapy but reported to induce leukoencephalopathy. Carmofur (Fig 1g) with the general formula of C 11 H 16 FN 3 O 3 S and a mass number of 257g/mol, is an orally administered anticancer drug, verified by FDA and potent for usage in the treatment of breast, colorectal and other types of solid cancer 40 . It is less toxic, inhibiting human acid ceramidase (AC), and has been utilized clinically for several years 41 . An in vitro study has affirmed the potency of carmofur in terminating AC activities and the spread of cancer cells with a median effective concentration of 2965 nM 42 . Further studies revealed that the inhibition of fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA) by carmofur as well as its therapeutic activity against several inflammation-related diseases makes it a potential therapeutic candidate in the treatment of SARS-CoV-2 infections 43 . This was further corroborated by a very recent investigation, which confirmed the efficacy of carmofur in inhibiting SARS-CoV-2 main protease and broader effectiveness against the virus via an interaction between the crystal structure of the virus main protease and carmofur which could modify the catalytic (Cys145) properties of SARS-CoV-2 40

Presatovir is an off-label drug currently undergoing trials for its activity against coronavirus disease owing to its activity against the respiratory syncytial virus (RSV), a causative agent of lower respiratory tract infections. Presatovir is regarded as a candidate RSV fusion (F) protein inhibitor due to the pyrazolo[1,5-a] pyrimidine series of compounds containing a piperidine ring at 2-position of the pyrazolo[1,5-a] pyrimidine scaffold 44 . It has a general formula C 24 H 30 ClN 7 O 3 S and a mass number of 532g/mol (Fig 1h) . 

Chloroquine, a synthetic succedaneum of the cinchona alkaloid quinine isolated from cinchona tree bark, is a well-known antimalarial drug that was introduced into medicine in the 1940s. It is a widely used antimalarial agent that was discovered to possess a broad-spectrum antiviral capacity 45 .

Chloroquine, having a long history, is considered safe to inhibit parasitaemia levels in mosquitoes. Besides, it is widely used for the treatment of patients with malaria cases with mild and transitory side-effects. To date, many people currently use these two drugs; Chloroquine (CQ) and

Hydroxychloroquine (HCQ). A derivative of CQ and HCQ which is usually administered orally to treat malaria can also be applied to treat symptoms of rheumatoid arthritis, systemic and discoid lupus erythematosus, pemphigus, lichen planus, sarcoidosis, scleroderma polymyositis, and porphyria cutanea tarda. Chloroquine was found also to be an effective antiviral agent that inhibits SARS-CoV infection and spread 14 In a physiologically-based model in vitro study of CQ and HCQ on SARS-CoV-2 Vero cells of some infected patients, an oral loading dose of 400 mg twice daily at day 1 followed by an oral maintenance dose of 200 mg twice daily for 4 days was recommended 52 . The results of the authors further displayed half-maximal effective concentration (EC 50s ) of 0.72% and 5.47% μM for HCQ and CQ respectively.

Additionally, it has been reported that the effect of HCQ on COVID-19 patients could be significantly improved with azithromycin 53 . At variance, a report document detailed that a long-term and combined usage of CQ or HCQ with any other drugs (such as azithromycin) induce QTc interval prolongation besides other severe side-effects like arrhythmogenic and cardiac problems, QRS widening, and negative entropy. CQ and HCQ are notable for inhibiting the P-glycoprotein transport system (in gut luminal and blood-brain barrier endothelial cells), which in turn increase cyclosporine and digoxin levels and ultimately to a more severe complicated result. Since the mode of actions of CQ and HCQ are identical, their activity on the virus may probably be the same. In a multinational registry analysis conducted on SARS COV-2 patients from 671 hospitals in six continents, who were placed on CQ, HCQ, the combination of antibiotics or without combination as a macrolide, there was a strong indication that CQ and HCQ when used alone or with antibiotics as drug regimens were associated with an increased frequency of ventricular arrhythmias and mortality rates in hospital among SARS COV-2 Teicoplanin was previously known as Teichomycin A 2 because it was co-purified together with moenomycin-like teichomycin A 1 that was isolated from a soil sample in India in 1978. [59] [60] [61] It acts as a glycopeptide that binds with the D-ala-D-ala terminus of the lipid (II) in the peptidoglycan to cause bacterial cell deaths and is being used in many nations to combat infections and multiple drug antibiotics resistance pathogens such as Staphylococcus aureus 60 . The complexity of Teicoplanin is that it is a mixture of different derivatives of closely related compounds and possibly be differentiated based on their length, the aliphatic chains, and its possible mechanism. The chemistry, biosynthesis alongside the gene-phylogenetic studies has been discussed [61] [62] [63] [64] . Teicoplanin is an antibiotic (Fig 1i) 

Among several potential drugs tested against SARS-CoV-2, Azithromycin is a broad-spectrum antibiotics macrolide that is currently in use for the management of infected patients in many countries

based on an open-label non-randomized clinical trial 53, 73 . It is a well-known brand and a 15-membered ring macrolide (azalide) antibiotic. This drug 9-deoxy-9a-aza-9a-methyl-9a-homoerythomycin only suppress bacterial infections in the host. As earlier pointed out that in combination with chloroquine, azithromycin causes a significant improvement in patients with malaria without any indication of risk due to QTc prolongation above that of chloroquine. [85] [86] [87] The addition of zinc sulphate alongside hydroxychloroquine and azithromycin played an important role in the increased number of SARS COV-2 patients being discharged therefore zinc sulphate can also be used as prophylaxis 88 .

In Morocco, it was reported that concomitant administration of hydroxychloroquine and azithromycin increased the number of cured SARS COV-2 patients and decreased death rates 89 . Azithromycin was also reported to be compatible with breastfeeding coronavirus nursing mothers and during pregnancy but with caution and adequate monitoring 90 . Notably, treatment with azithromycin combined with hydroxychloroquine showed a more prolonged QTc than treatment with only azithromycin 91 

Ivermectin is an anti-parasitic broad-spectrum drug that was reported to inhibit the interaction between HIV-1 replicates 95 . Chemically, the compound reveals two subsets: the 1 st subset possesses an olefinic bond at C-22 while the 2 nd subset bond is hydrated with a hydroxyl (-OH) group at position 23 known as 22, 23-dihydro derivative of avermectin B 1 which is a macrolide lactone produced by actinomycetes Streptomyces avermitilis 96 . Utilizations of ivermectin are numerous and potent to combat other viruses that have been fully documented [97] [98] [99] [100] . This broad-spectrum activity on viruses is due to the importin alpha/beta 1 during infection 101, 102 . Quest for drugs to combat this novel coronavirus revealed a possible role for ivermectin and importin alpha/beta-1 during infection as a signal-dependent nucleocytoplasmic shuttling of the SARs-CoV nucleocapsid protein mediated nuclear import [103] [104] [105] [106] . In Australia, the antiviral activity of ivermectin on SARS COV-2 infected cells in an in-vitro study revealed a 93 per cent reduction in the viral RNA present in the supernatant and 99.8 per cent reduction in cell-associated with viral RNA. It was observed that ivermectin treatment led to a rapid reduction in viral RNA load by about 5000-fold in 48 hours 104 . The pharmacokinetic perspective of this drug was analysed based on the pharmacokinetic data from clinically relevant and excessive dosing studies available; It was indicated that the SARS-CoV-2 inhibitory concentrations are not likely to be attainable in humans and that a single dosage is practically inappropriate because of the infected cells which were exposed at different concentrations negate the pharmacokinetics findings of some previously used doses pooled in the treatment regimen of ivermectin 107 and therefore suggests a need for further clinical trials to determine the best level of inhibitory concentration. It was reported that the combination of ivermectin and hydroxychloroquine could work synergistically with adequate clinical monitoring when administered 108 . In a screening of 1408 patients gathered from 3 continents and carefully matched with age, gender/ethnicity, comorbidities, and illness severity score group consideration; it was concluded that administration of ivermectin on COVID patients decreased death rates and reduced the length of hospital admission with the hope that an ivermectin drug used for filarial worm treatment (a neglected tropical disease) would be potent enough to combat the current SARS COV-2 alongside with clinical trials on the standard practices 109 . However, some researchers suspected possible toxicity with the use of ivermectin but recommended careful consideration of risk-benefit ratios and clinical trials to fully understand the pharmacokinetics and safety of administration 110, 111 . It was demonstrated that both ivermectin and chloroquine are capable to inhibit replication of the SARS COV-2 invitro with a suggestion that a combination of these drugs could be effective especially in malaria-endemic regions where chloroquine is still an effective drug to combat Plasmodium vivax blood-stage therapeutic 112 

This is an isoquinoline alkaloid originated from Colchicum autumnale belonging to the family of Liliaceae 113 . Traditionally, it has been used in gout management, Mediterranean fever, liver cirrhosis, chronic myelocytic leukaemia, hepatic disorders, cardiovascular diseases, and also in potential anticancer drugs 114, 115 . The biosynthesis of colchicine involves mainly phenylalanine and tyrosine. It is a very toxic antitumor drug and has been reported in patients with kidney and liver failure, however, derivatives such as dem-colchicine, trimethyl colchicine acid methyl ester, 2-dimethyl thiocolchicine, 3-dimethyl thiocolchicine and the biosynthetic colchicine's which are less toxic are used as antileukaemia agents 116, 117 . Colchicine has anti-inflammatory effects on the IL-1 and IL-6 axes which further prolong neutrophils and macrophages actions as well as the multiple cellular actions in the assembly of the nucleotide-binding domain and leucine-rich repeat protein inflammasome 118 . It is a non-selective inhibitor of Nucleotide Oligomerization Domain)-like receptor protein 3 (NLRP3) inflammasome that plays a huge role in anti-inflammatory diseases and binds to unpolymerized tubulin heterodimers, forming a stable complex that can effectively inhibit microtubule dynamics upon binding to microtubules ends 118, 119 . In addition to this, colchicine plays an important role in managing patients with SARS COV-2 especially patients with myocardial infarction related cases even at acute and chronic phase periods 120 . Colchicine was recommended possibly on its clinical trial to see if it could assist in the clinical management of SARS COV-2 patients and reduce the inflammation caused by the virus 121 . According to 122 , severe acute respiratory infections can cause pulmonary and systemic inflammation among SARS COV-2 patients and could lead to cardiac injury, heart failure, and respiratory complications. Significant evidence was reported that colchicine could ameliorate the effect of inflammation and hyper inflammation activity on SARS COV-2 patients and that it could be used as a supporting therapy with possible clinical trials suggested 123 . In another study, there was a significant finding on the physicochemical properties, chemical properties, and the mechanism of action and the conclusion that it may not be beneficial to patients since it has effects of increasing cytosolic pH and by implication might increase the rate of acute respiratory distress syndrome and multiple organ failure among SARS COV-2 patients 124 . In Israel, experimental studies were conducted using real-world data, a conclusion was reached that colchicine could be utilized based on the NLRP3 inflammasome which can be activated and triggered by different SARS-CoV-2 proteins and therefore could lead to severe adult respiratory distress syndrome. 125 Camostat mesylate, a protease inhibitor and observed a partial inhibition at the entry stage of the SARS COV-2 virus in the epithelial lung cells. This suggests that protease inhibitors could combat the novel 2019 coronavirus. Furthermore, the authors argued that Nafamostat mesylate offered more antiviral protection than camostat mesylate (Foipan) which is in use in Japan to treat SARS-CoV-2 infected patients. They also proposed that Nafamostat mesylate should be subjected to clinical investigations to evaluate its curative activity and strength to inhibit SARS COV-2 and further recommended that camostat mesylate, Nafamostat, and bromhexine hydrochloride (BHH) be considered for inhibition of TMPRSS2 in the control of COVID-19 138 . Interestingly, in a large cohort study especially on African-American SARS COV-2 male patients diagnosed with Diabetes mellitus and Asthma using their sputum cells, the result showed that there was a higher expression of ACE2 and TMPRSS2 in diabetics patients with lower expression of ACE2 and TMPRSS2 in asthmatic patients. This suggests further investigation into the effective regimen among people with diabetes and asthma COVID-19 patients with effective monitoring including its role in the lung, renal, heart, and neurones of patients with SARS COV-2 [139] [140] [141] . Bestle et al. 142 found out that TMPRSS2, as well as FURIN protease enzymes which are abundant in the respiratory tract, could activate their surface glycoprotein and this suggests that they are potential drugs in the treatment of SARS COV-2.

Interferon-a and b are naturally broad-spectrum antiviral active agents (Fig 1j) . The administration of IFNs can be used as prophylaxis as well as early therapy based on the principle of "supplement to 

It was noticed that there are different dosage regimens, drug combination trials, and skill-based experience treatment by clinicians on different patients with an underlying medical health history. This posits complications in many developing and low-income countries with little or no quality standard health coverage in managing the post-SARS-CoV-2 health crisis. There is a need for more research and investigations into the lead specific drugs that could cure and manage the confirmed cases with the expectation of producing an effective and accessible vaccine to curtail the virus spread. Also, adequate monitoring of dosage regimen and drug combination, as well as ethical consideration, should be ensured while dealing with COVID-19 potential experimental drugs. Although, it is a pandemic situation, human rights to life including choice of drugs, allergy, pains and other difficult challenges and quality laboratory investigations before clinical trials should be considered. Safe health record-keeping, monitoring, toxicity check, dosage formulation, dug-drug interaction, mechanism of action, and side effect are paramount especially as post-COVID health-related management is concerned. However, it was advised that couples should avoid pregnancy during the pandemic and in-vitro fertilization should be carefully examined to prevent the potential threat to developing embryos 147 in spite no evidence of SARS COV-2 virus in semen of males recovering from the novel coronavirus after 30 days of diagnosis 148 . This also suggests quality and adequate examination of new-born babies during this pandemic to ensure they are not carriers of the COVID-19 virus. Furthermore, unprotected sexual related activities should be cautioned while it is hoped there would be scientific investigations into the protective measures during sexual intercourse.

Access to a clean environment, clean water, quality life, housing and basic amenities should be continually ensured by governments and health organizations to meet the Global Health Security Agenda (GHSA) which could help alleviate some potential human health risks, especially among developing countries.

This review has highlighted reported curative antiviral drugs and broad-spectrum antibiotics (both traditional and orthodox) used in the treatment of SARS-CoV-2; their chemistry, botanical sources, and active components as well as possible clinical trials and safety information. However, there is still a need for continued investigation of herbal medicines and isolation of compounds that could completely inhibit the virus. A full understanding of their mode of action which would help in drug development needs to be known. Further in-depth studies on vaccines and molecular investigations into potential RNA targets should be a crucial priority. Best practices for virus prevention which include observing personal hygiene, following health guidelines by a way of physical distancing, and social responsibility among people are important in alleviating the coronavirus spread.

Pneumonia outbreak associated with a new coronavirus of probable bat origin

World Health Organization. Coronavirus disease (COVID-2019) situation reports

Middle East respiratory syndrome coronavirus (MERS-CoV)

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Severe acute respiratory syndrome-related coronavirus: The species and its viruses a statement of the Coronavirus Study Group

Drug firms mobilize to combat the coronavirus outbreak

Coronavirus latest: death toll passes 2,000

ChemDraw Ultra 9.0. CambridgeSoft, 100 CambridgePark Drive, Cambridge, MA 02140. www. cambridgesoft.com. See Web site for pricing options

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients

The broad-spectrum antiviral agent ribavirin inhibits capping of mRNA

Treatment with interferon-2b and ribavirin improves outcome in MERS-CoVinfected rhesus macaques

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

A Low-Fat Vegan Diet Improves Glycemic Control and Cardiovascular Risk Factors in a Randomized Clinical Trial in Individuals with Type 2 Diabetes

Effective Chemicals against Novel Coronavirus (COVID-19) in China

Favipiravir as a potential countermeasure against neglected and emerging RNA viruses

Favipiravir (T-705), a broad-spectrum inhibitor of viral RNA polymerase

Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment

Arbidol: a broad-spectrum antiviral compound that blocks viral fusion

Arbidol as a broad-spectrum antiviral: an update

Efficacy and tolerability of lopinavir/ritonavir-and efavirenz-based initial antiretroviral therapy in HIV-1-infected patients in a tertiary care hospital in Beijing

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Interpretation of "guidelines for the Diagnosis and treatment of novel coronavirus (2019-nCoV) infection by the national health commission (trial version 5

Arbidol/IFN-a2b therapy for patients with coronavirus disease 2019: a retrospective multicenter cohort study. Microbes and Infection

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

Discovery and Synthesis of a phosphoramidite prodrug of a pyrrolo[2,1-f][triazin-4-amino]adenine-nucleoside (GS-5374)for the treatment of Ebola and Emerging virus

Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

COVID-19 in Latin America: the implications of the first confirmed case in Brazil

Coronavirus susceptibility to the Antiviral Remedsvir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Broad-spectrum antiviral remdesivir inhibits human endemic and zoonotic delta coronaviruses with a highly divergent RNA dependent RNA polymerase

Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys

Ebola virus relapse causing meningoencephalitis: A case report

Atazanavir: a review of its use in the management of HIV-1 infection

Atazanavir/ ritonavir: a review of its use in HIV therapy

Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model

Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Natura structs

Zihe Rao & Haitao Yang. Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors

Review of a new antimetabolic agent 1-hexylcarbamoyl-5-fluorouracil (HCFU). Recent Results Cancer Res

Discovery of highly potent acid ceramidase inhibitors with in vitro tumour chemosensitizing activity

A New Use for an Old Drug: Carmofur Attenuates Lipopolysaccharide (LPS)-Induced Acute Lung Injury via Inhibition of FAAH and NAAA Activities

Design and Synthesis of 2-(1-Alkylaminoalkyl) pyrazolo[1,5-a] pyrimidines as New Respiratory Syncytial Virus Fusion Protein Inhibitors Chemical and

New insights into the antiviral effects of chloroquine

Chloroquine for 2019 novel coronavirus SARS-CoV-2

Teicoplanin potently blocks the cell entry of

COVID-19: An update on the epidemiological, clinical, preventive, and therapeutic evidence and guidelines of integrative Chinese Western Medicine for the Management of the 2019 novel coronavirus

A Systematic Review on the Efficacy and Safety of CHlorquine for the Treatment of COVID-19

Breakthrough: Chloroquine phosphate has shown apparent efficacy in the treatment of COVID-19 associated pneumonia in clinical studies

Novel Natural Products: Therapeutic Effects in Pain, Arthritis, and Gastrointestinal Diseases. Progress in Drug Research

In-vitro antiviral activity and Projection of Optimized dosing design of the Hydroxychloroquine for the treatment of Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

Incidence of teicoplanin adverse drug reactions among patients with vancomycin-associated adverse drug reactions and its risk factors

Glycopeptide antibiotics: Back to the future

Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3

Old and new glycopeptide antibiotics: From product to gene and back in the post-genomic era

Teicoplanin biosynthesis: Unraveling the interplay of structural, regulatory, and resistance genes

Teicoplanin: An alternative drug for the treatment of COVID-19

Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections

Core regulatory components of the PHO pathway are conserved in the methylotrophic yeast Hansenula polymorpha

Origin, structure, and activity in vitro and in vivo of dalbavancin

Treatment options for COVID-19: The reality and challenges

Teicoplanin potently blocks the cell entry of 2019-nCoV

Teicoplanin A Review of its Antibacterial Activity, Pharmacokinetic Properties, and Therapeutic Potential

A Review of Teicoplanin Used in the Prevention and Treatment of Serious Infections Caused by Gram-Positive Bacteria and Compared Its Effects with Some Other Antibiotics

Novel antiviral activities of obatoclax, emetine, niclosamide, brequinar, and homoharringtonine

Azithromycin-Review of key chemical, pharmacokinetics and microbiological features 1996

Azithromycin (Zithromax(R). 1996;6. (Book)

Azithromycin and COVID-19 History and Review

Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit

The potential use of hydroxychloroquine, Ivermectin, and Azithromycin drugs in fighting COVID-19: Trends, scope and relevance

Response to the editorial "COVID-19 in patients with cardiovascular diseases

Should azithromycin be used to treat COVID-19? A rapid review

Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection

Risk of QT Interval Prolongation Associated with Use of Hydroxychloroquine with or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)

The Effect of Chloroquine

In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19

Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: A multinational, network cohort and self-controlled case series study

Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: Outcomes in hospitalized COVID-19 patients

African exemplary steps in fighting against COVID-19: A Moroccan example 2020

Use of azithromycin during pregnancy and breastfeeding: A coronavirus pandemic (COVID-19) update. 2020;10

Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: Implications for QT Interval Monitoring

Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin

A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on the viral carriage in patients with COVID-19

High-Risk COVID-19SARS COV-2: Potential Intervention at Multiple Points in the COVID-19 Disease Process Via Prophylactic Treatment with Azithromycin or Bee Derived Products

An AlphaScreen(R)-based assay for high-throughput screening for specific inhibitors of nuclear import

A study of the variability of the endogenous energy output by adult roosters and a determination of the available energy of nine different feedstuffs

Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug

Nuclear localization of dengue virus (DENV) 1-4 nonstructural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin

Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import

A Review of SARS-CoV-2 and the Ongoing Clinical Trials

Nuclear trafficking of proteins from RNA viruses: a potential target for anti-virals Antivir

Inhibitors of nuclear transport

Nucleocytoplasmic transport of nucleocapsid proteins of enveloped RNA viruses

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Recognition of potential Covid-19 drug treatments through the study of existing protein-drug and protein-protein structures: An analysis of kinetically active residues

An Update on Current Therapeutic Drugs Treating COVID-19

Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view

Infectious Diseases (except HIV/AIDS)

Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment

Ivermectin and Novel Coronavirus Disease (COVID-19): Keeping Rigor in Times of Urgency. The American Journal of Tropical Medicine and Hygiene

White paper on Ivermectin as a potential therapy for COVID-19 2020

Lohmer LR. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19

Safety, pharmacokinetics, and liver-stage Plasmodium cynomolgi effect of high-dose ivermectin and chloroquine in Rhesus Macaques

Chemistry of colchicine

Colchicine: An ancient drug with novel applications

Cytotoxic Colchicine Alkaloids: From Plants to Drugs

Colchicine-Update on mechanisms of action and therapeutic uses

Colchicine and its various physicochemical and biological aspects

Microtubule-driven Spatial Arrangement of Mitochondria Promotes Activation of the NLRP3 Inflammasome

Roberto Perricone, and Roberto Gerli The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19

The Greek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): Rationale and study design

Cytokine storm and colchicine potential role fighting SARS-CoV-2 pneumonia

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study

Possible ameliorative effect of colchicine on the prevention of cytokine storm and its associated hyper-inflammation in patients with COVID-19

Colchicine may not be effective in COVID-19 infection; it may even be harmful?

Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis

Reflections on the number of independent solutions for forest spatial harvest scheduling problems: a case of simulated annealing

Homoharringtonine in Combination with cytarabine and aclarubicin resulted in a high complete remission rate after the first induction therapy in a patient with denovo acute myeloid leukaemia

Wang jianmin Homoharringtonine and omacetaxine for myeloid haematological malignancies

FDA 2012

The natural compound homoharringtonine presents broad antiviral activity in vitro and in vivo

Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumours

Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV2-Priming Protease TMPRSS2

COVID 19: Camostat and The Role of Serine Protease Entry Inhibitor TMPRSS2

Ontological and Bioinformatics Analysis of Anti-Coronavirus Drugs and Their

TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? Cancer Discovery, candisc

Nafamostat mesylate blocks activation of SARS-CoV-2: New treatment option for COVID-19

Homology Modeling and Docking Studies of TMPRSS2 with Experimentally Known Inhibitors Camostat Mesylate, Nafamostat, and Bromhexine Hydrochloride to Control SARS-Coronavirus-2

ACE inhibition and cardiometabolic risk factors, lung ACE2 and TMPRSS2 gene expression, and plasma ACE2 levels: A Mendelian randomization study

TMPRSS2) inhibitors as potential therapeutics for SARS-CoV-2 coronavirus. 6

Genetic analysis of the novel SARS-CoV-2 host receptor TMPRSS2 in different populations

Böttcher-Friebertshäuser E. TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets

et al Treatment with Lopinavir/ritonavir or interferon-Beta1b improves the outcome of MERS-CoV infection in a no human primate model of the common marmoset

Coronavirus drug discovery and therapeutics options

COVID-19 and emerging viral infections: The case for interferon lambda

COVID 19: Lambda Interferon Against Viral Load and Hyperinflammation

Single-Cell RNA-seq Identifies Cell Subsets in Human Placenta That Highly Expresses Factors to Drive Pathogenesis of SARS-CoV-2

No evidence of SARS-CoV-2 in the semen of males recovering from COVID-19

Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.2020b

Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19

Atazanavir Inhibits SARSCoV-2 Replication and Pro-Inflammatory Cytokine Production. BioRxiv

Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century

High-throughput screening and identification of potent broad-spectrum inhibitors of coronaviruses

Advances in respiratory virus therapeutics -A meeting report from the 6 th Antiviral Group conference

New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19?

Hydroxychloroquine versus Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS) Protocol for a Pragmatic, Open-Label

Colchicine in COVID-19: An Old Drug, New Use

Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies

Type I and Type III Interferons -Induction, Signaling, Evasion, and Application to Combat COVID-19

Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) medRxiv preprint DOI

Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV

Acknowledgement: We acknowledge the painstaking efforts of the anonymous reviewers toward the enhanced improvement of this work.Funding: This review article did not receive any grant from funding agencies.

Authors' contribution: All authors contributed equally and approved the final version of the manuscript.

Authors declare no conflict of interest.